Clinico-pathologic Parameters for Prediction of Microsatellite Instability in Colorectal Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Although the incidence of microsatellite instability (MSI) accounts for 10-15% of cases of colorectal cancer, its clinical application for all colorectal cancers has widened. We attempted to identify clinical and pathological parameters that may be helpful in selection of patients with MSI-high (MSI-H). Materials and Methods A total of 120 resected colorectal cancers were enrolled retrospectively for this MSI study. Polymerase chain reaction (PCR) and denaturing high performance liquid chromatography and/or real time PCR methods with five markers and immunohistochemistry (IHC) for MLH1 and MSH2were performed for analysis of cancer and blood specimens. Clinico-pathologic parameters,including IHC, were investigated in order to determine their usefulness as predictive factors of MSI. Results Among 120 cases of colorectal cancer, MSI was observed in 15 cases (12.5%), including 11 cases of MSI-H and four cases of MSI-low. Patients with MSI were younger, less than 50 years old, had a family history of cancer, Rt. sided colon cancer and/or synchronous multiple colorectal cancer,mucinous histologic type, and serum carcinoembryonic antigen group in the normal range. Results of multivariate analysis showed Bethesda guidelines, Rt. sided and/or synchronous multiple colorectal cancer, and negative expression of IHC for MLH1, which was consistently associated with MSI-H. MSI-H colorectal tumors have met at least one of these three parameters and their sensitivity and specificity were 100% and 72.5%, respectively. Conclusion Bethesda guidelines, tumor location, and negative expression of MLH1 protein are important parameters for selection of patients with colorectal cancers for MSI testing. MSI testing is recommended for patients showing any of these three parameters.
Abstract
Purpose Although the incidence of microsatellite instability (MSI) accounts for 10-15% of cases of colorectal cancer, its clinical application for all colorectal cancers has widened. We attempted to identify clinical and pathological parameters that may be helpful in selection of patients with MSI-high (MSI-H). Materials and Methods A total of 120 resected colorectal cancers were enrolled retrospectively for this MSI study. Polymerase chain reaction (PCR) and denaturing high performance liquid chromatography and/or real time PCR methods with five markers and immunohistochemistry (IHC) for MLH1 and MSH2were performed for analysis of cancer and blood specimens. Clinico-pathologic parameters,including IHC, were investigated in order to determine their usefulness as predictive factors of MSI. Results Among 120 cases of colorectal cancer, MSI was observed in 15 cases (12.5%), including 11 cases of MSI-H and four cases of MSI-low. Patients with MSI were younger, less than 50 years old, had a family history of cancer, Rt. sided colon cancer and/or synchronous multiple colorectal cancer,mucinous histologic type, and serum carcinoembryonic antigen group in the normal range. Results of multivariate analysis showed Bethesda guidelines, Rt. sided and/or synchronous multiple colorectal cancer, and negative expression of IHC for MLH1, which was consistently associated with MSI-H. MSI-H colorectal tumors have met at least one of these three parameters and their sensitivity and specificity were 100% and 72.5%, respectively. Conclusion Bethesda guidelines, tumor location, and negative expression of MLH1 protein are important parameters for selection of patients with colorectal cancers for MSI testing. MSI testing is recommended for patients showing any of these three parameters.
참고문헌 (25)
- 오승엽, "산발성 대장암에서 현미부수체 불안정성의 임상병리학적 의의", 대한외과학회지, 71(6), pp.420~425 (2006), 대한외과학회
- Sheng JQ, "Genetic diagnosis strategy of hereditary non-polyposis colorectal cancer", World J Gastroenterol, 15, pp.983~989 (2009)
- Woods MO, "The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease", Gut, 59, pp.1369~1377 (2010)
- Wheeler JM, "The role of hypermethylation of the hMLH1 promoter region in HNPCC versus MSI+ sporadic colorectal cancers", J Med Genet, 37, pp.588~592 (2000)
- Watanabe T, "Chemotherapy and survival in colorectal cancer patients with and without microsatellite instability: can MSI be a prognostic marker?", Gastroenterology, 127, pp.688~689 (2004)
- Vasen HF, "The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer(ICG-HNPCC)", Dis Colon Rectum, 34, pp.424~425 (1991)
- Rodriguez-Bigas MA, "A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome : meeting highlights and Bethesda guidelines", J Natl Cancer Inst, 89, pp.1758~1762 (1997)
- Alexander J, "Histopathological identification of colon cancer with microsatellite instability", Am J Pathol, 158, pp.527~535 (2001)
- Shia J, "Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer", Am J Surg Pathol, 27, pp.1407~1417 (2003)
- Shia J, "Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms", Am J Surg Pathol, 29, pp.96~104 (2005)
- Suraweera N, "Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR", Gastroenterology, 123, pp.1804~1811 (2002)
- Dietmaier W, "Detection of microsatellite instability by real time PCR and hybridization probe melting point analysis", Lab Invest, 81, pp.1453~1456 (2001)
- Horii A, "Frequent replication errors at microsatellite loci in tumors of patients with multiple primary cancers", Cancer Res, 54, pp.3373~3375 (1994)
- Karnes WE Jr, "Reduced COX-2 protein in colorectal cancer with defective mismatch repair", Cancer Res, 58, pp.5473~5477 (1998)
- Carethers JM, "Mismatch repair proficiency and in vitro response to 5-fluorouracil", Gastroenterology, 117, pp.123~131 (1999)
- Sutter C, "Molecular screening of potential HNPCC patients using a multiplex microsatellite PCR system", Mol Cell Probes, 13, pp.157~165 (1999)
- Loukola A, "Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer(HNPCC)", Cancer Res, 61, pp.4545~4549 (2001)
- Zhou XP, "Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites", Genes Chromosomes Cancer, 21, pp.101~107 (1998)
- Samowitz WS, "BAT-26 and BAT-40 instability in colorectal adenomas and carcinomas and germline polymorphisms", Am J Pathol, 154, pp.1637~1641 (1999)
- Salovaara R, "Populationbased molecular detection of hereditary nonpolyposis colorectal cancer", J Clin Oncol, 18, pp.2193~2200 (2000)
- Umar A, "Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer(Lynch syndrome)and microsatellite instability", J Natl Cancer Inst, 96, pp.261~268 (2004)
- Wullenweber HP, "Evaluation of Bethesda guidelines in relation to microsatellite instability", Dis Colon Rectum, 44, pp.1281~1289 (2001)
- Ward R, "Microsatellite instability and the clinicopathological features of sporadic colorectal cancer", Gut, 48, pp.821~829 (2001)
- Engel C, "Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer", Int J Cancer, 118, pp.115~122 (2006)
- Lanza G, "Immunohistochemical pattern of MLH1", MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability, 2002, pp.15, 741~749